Avantel reported a 35% year-on-year rise in consolidated revenue to ₹70.42 crore for the quarter ended June 2026. However, consolidated profit after tax saw a significant jump of 67%, reaching ₹5.39 crore. The company also announced board appointments.
Avantel Limited: Strong Core Growth in Q1 FY27 Offset by Healthcare Segment Losses
Avantel's consolidated revenue for the quarter ended June 30, 2026, stood at ₹70.42 crore, a notable increase of 35.6% from ₹51.91 crore in the comparable period. Consolidated profit after tax (PAT) surged by 66.9% to ₹5.39 crore, compared to ₹3.23 crore in the same period last year.
Reader Takeaway: Strong core segment growth drives revenue; healthcare losses pressure consolidated profits.
What just happened
Avantel Limited announced its financial results for the first quarter of Fiscal Year 2027 (ending June 30, 2026). The company reported a consolidated revenue of ₹70.42 crore, a significant jump from ₹51.91 crore in the prior year's comparable quarter. Consolidated profit after tax (PAT) rose to ₹5.39 crore from ₹3.23 crore year-on-year.
Standalone revenue also saw robust growth, reaching ₹70.12 crore from ₹51.84 crore, with standalone PAT increasing to ₹7.62 crore from ₹4.62 crore.
Why this matters
The results indicate strong operational performance in Avantel's core business, Communications & Signal Processing. However, the losses from the Healthcare segment, particularly its subsidiary iMeds Global Private Limited, continue to impact the consolidated profitability. The appointment of a new Director for Operations suggests a focus on improving overall operational efficiency.
The backstory
Avantel operates in two primary segments: Communications & Signal Processing and Health Care. Historically, the Communications segment has been the main profit generator, while the Healthcare segment has faced challenges. The company's reliance on government contracts for its core business provides a stable revenue base but also presents concentration risks.
What changes now
Avantel has approved the re-appointment of Mr. Abburi Siddhartha Sagar as Executive Director and appointed Mr. Peddi Bala Bhaskar Rao as Director (Operations). Mr. Sagar's remuneration has been revised. These corporate actions, subject to shareholder approval via postal ballot, signal a focus on leadership and operational enhancement. Investors will be watching the impact of the new Director (Operations) on the company's performance.
Risks to watch
The primary risk remains the consistent losses from the Healthcare segment, which pulled down consolidated PAT despite strong standalone performance. The company's heavy reliance on a principal customer controlled by the Government of India creates significant customer concentration risk. Additionally, employee benefit expenses include non-cash charges from ESOPs, which affect reported profits.
Peer comparison
(No peer comparison data available in the filing.)
Context metrics (time-bound)
- Consolidated Revenue (Q1 FY27): ₹70.42 crore (up 35.6% YoY)
- Consolidated PAT (Q1 FY27): ₹5.39 crore (up 66.9% YoY)
- Standalone Revenue (Q1 FY27): ₹70.12 crore (up 35.3% YoY)
- Standalone PAT (Q1 FY27): ₹7.62 crore (up 65.3% YoY)
- Communications Segment Profit: ₹10.92 crore
- Healthcare Segment Loss: ₹2.22 crore
What to track next
Investors should monitor the outcome of the upcoming Postal Ballot for shareholder approval of the board appointments. Additionally, tracking the performance of the Healthcare segment and any strategic initiatives to improve its profitability will be crucial. The company's ability to manage customer concentration risks and leverage its core segment's strengths will also be key.